The present invention refers to a pharmaceutical composition which, in addition to allowing or producing an effective and specific immune response against Aβ40 (the antibodies produced are specific for Aβ40 without significantly binding to Aβ42), increases said response compared with the response produced by other conjugates also comprising CysAβ(33-40) peptide and KLH, and in which said elements have been bound or conjugated by means of another crosslinking agent that also allow the binding of a peptide to the transport protein.Conjugado amiloide y usos y procedimientos del mismo.#Conjugado que comprende al menos un péptido CisA{be}(33-40) (SEQ ID NO: 1) y hemocianina de lapa californiana (KLH), caracterizado porque el agente entrecruzante que conecta cada uno de los componentes del conjugado es el éster de N-hidroxisuccinimida del ácido maleimido butírico (SM) composiciones que comprenden dicho conjugado y usos y procedimientos relacionados con las mismas.
